Veliter Biomedical Technology
One-Stop Oligo CDMO Solutions from Preclinical to Commercial
Commitment to Quality
Premier Partner of Gene Therapy Medicine Innovators
Veliter Biomedical Technology
Guangdong Veliter Biomedical Technology Co., Ltd, founded in July 2019, led by experts with specialized knowledge unique to oligonucleotide process development and manufacturing, tens of years of experience in pre-clinical and clinical development of innovative oligo drug products, come from globally recognized pharmaceutical enterprises and CDMO firms, specializes in phase appropriate analytical method development/validation, process development/validation, scale-up, non-GMP and GMP manufacturing, formulation, and CMC/regulatory solutions/services.
Our product portfolio encompasses Deoxyribonucleic acid (DNA), Ribonucleic acid (RNA), Phosphorodiamidate morpholino oligonucleotides (PMO), and Peptide-conjugated phosphorodiamidate morpholino oligonucleotides (PPMO) which diversify into ASO, siRNA, miRNA, Aptamer, circleRNA, CpG ODN, sgRNA, among others.
Products & Services
Positive oligo program experience, from end to end
Focusing on your needs and building long-term partnerships, your own Veliter’s project manager will be flexible and responsive. This is Veliter’s approach to make your oligonucleotide program move smoothly through pre-clinical to commercial.
